Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma

Cancer Letters

Volumn 331, Issue 2, 2013, Pages 174-182

  Goto, Hiroki ^a   Matsuda, Kouki ^a   Srikoon, Pattaravadee ^a   Kariya, Ryusho ^a   Hattori, Shinichiro ^a   Taura, Manabu ^a   Katano, Harutaka ^b   Okada, Seiji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

AIDS; Primary effusion lymphoma; V 9V 2 T cell; Zoledronic acid

Indexed keywords

DEATH RECEPTOR; MEVALONIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL GRANULE; CONTROLLED STUDY; CYTOTOXICITY; EXOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOMA CELL; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR XENOGRAFT; VGAMMA9VDELTA2 T LYMPHOCYTE;

ANIMALS; CELL PROLIFERATION; DIPHOSPHONATES; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; LYMPHOMA, PRIMARY EFFUSION; MICE; MICE, INBRED NOD; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875364947     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.021     Document Type: Article

References (47)

1. Cesarman E., Chang Y., Moore P.S., Said J.W., Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 1995, 332:1186-1191.
2. Nador R.G., Cesarman E., Chadburn A., Dawson D.B., Ansari M.Q., Sald J., Knowles D.M. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996, 88:645-656.
3. Simonelli C., Spina M., Cinelli R., Talamini R., Tedeschi R., Gloghini A., Vaccher E., Carbone A., Tirelli U. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J. Clin. Oncol. 2003, 21:3948-3954.
4. Boulanger E., Gerard L., Gabarre J., Molina J.M., Rapp C., Abino J.F., Cadranel J., Chevret S., Oksenhendler E. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J. Clin. Oncol. 2005, 23:4372-4380.
5. Parker C.M., Groh V., Band H., Porcelli S.A., Morita C., Fabbi M., Glass D., Strominger J.L., Brenner M.B. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J. Exp. Med. 1990, 171:1597-1612.
6. Evans P.S., Enders P.J., Yin C., Ruckwardt T.J., Malkovsky M., Pauza C.D. In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology 2001, 104:19-27.
7. Gomes A.Q., Martins D.S., Silva-Santos B. Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res. 2010, 70:10024-10027.
8. Bonneville M., O'Brien R.L., Born W.K. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 2010, 10:467-478.
9. Roelofs A.J., Jauhiainen M., Monkkonen H., Rogers M.J., Monkkonen J., Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 2009, 144:245-250.
10. Godoy-Ramirez K., Makitalo B., Thorstensson R., Sandstrom E., Biberfeld G., Gaines H. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A 2005, 68:71-80.
11. Katano H., Sato Y., Kurata T., Mori S., Sata T. High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. Am. J. Pathol. 1999, 155:47-52.
12. Davodeau F., Peyrat M.A., Hallet M.M., Gaschet J., Houde I., Vivien R., Vie H., Bonneville M. Close correlation between Daudi and mycobacterial antigen recognition by human gamma delta T cells and expression of V9JPC1 gamma/V2DJC delta-encoded T cell receptors. J. Immunol. 1993, 151:1214-1223.
13. Clezardin P. The antitumor potential of bisphosphonates. Semin. Oncol. 2002, 29:33-42.
14. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005, 12:228-237.
15. Das H., Groh V., Kuijl C., Sugita M., Morita C.T., Spies T., Bukowski J.F. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001, 15:83-93.
16. Betts M.R., Brenchley J.M., Price D.A., De Rosa S.C., Douek D.C., Roederer M., Koup R.A. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 2003, 281:65-78.
17. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 2004, 294:15-22.
18. Goto H., Kariya R., Shimamoto M., Kudo E., Taura M., Katano H., Okada S. Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-kappaB pathway. Cancer Sci. 2012.
19. Toomey N.L., Deyev V.V., Wood C., Boise L.H., Scott D., Liu L.H., Cabral L., Podack E.R., Barber G.N., Harrington W.J. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 2001, 20:7029-7040.
20. Wu W., Rochford R., Toomey L., Harrington W., Feuer G. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk. Res. 2005, 29:545-555.
21. Keller S.A., Schattner E.J., Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000, 96:2537-2542.
22. Klass C.M., Krug L.T., Pozharskaya V.P., Offermann M.K. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005, 105:4028-4034.
23. De Maria A., Ferrazin A., Ferrini S., Ciccone E., Terragna A., Moretta L. Selective increase of a subset of T cell receptor gamma delta T lymphocytes in the peripheral blood of patients with human immunodeficiency virus type 1 infection. J. Infect. Dis. 1992, 165:917-919.
24. Martini F., Urso R., Gioia C., De Felici A., Narciso P., Amendola A., Paglia M.G., Colizzi V., Poccia F. Gammadelta T-cell anergy in human immunodeficiency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy. Immunology 2000, 100:481-486.
25. Cummings J.S., Cairo C., Armstrong C., Davis C.E., Pauza C.D. Impacts of HIV infection on Vgamma2Vdelta2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS. J. Leukoc. Biol. 2008, 84:371-379.
26. Ibrahim A., Scher N., Williams G., Sridhara R., Li N., Chen G., Leighton J., Booth B., Gobburu J.V., Rahman A., Hsieh Y., Wood R., Vause D., Pazdur R. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin. Cancer Res. 2003, 9:2394-2399.
27. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296:235-242.
28. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J.L., Schroter M., Scaffidi C., Krammer P.H., Peter M.E., Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
29. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., Huang A., Donahue C.J., Sherwood S.W., Baldwin D.T., Godowski P.J., Wood W.I., Gurney A.L., Hillan K.J., Cohen R.L., Goddard A.D., Botstein D., Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703.
30. Yu K.Y., Kwon B., Ni J., Zhai Y., Ebner R., Kwon B.S. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 1999, 274:13733-13736.
31. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., Heike T., Nakahata T. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
32. Sato K., Kimura S., Segawa H., Yokota A., Matsumoto S., Kuroda J., Nogawa M., Yuasa T., Kiyono Y., Wada H., Maekawa T. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer 2005, 116:94-99.
33. Todaro M., D'Asaro M., Caccamo N., Iovino F., Francipane M.G., Meraviglia S., Orlando V., La Mendola C., Gulotta G., Salerno A., Dieli F., Stassi G. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J. Immunol. 2009, 182:7287-7296.
34. D'Asaro M., La Mendola C., Di Liberto D., Orlando V., Todaro M., Spina M., Guggino G., Meraviglia S., Caccamo N., Messina A., Salerno A., Di Raimondo F., Vigneri P., Stassi G., Fournie J.J., Dieli F. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J. Immunol. 2010, 184:3260-3268.
35. Li H., Wang Y., Zhou F. Effect of ex vivo-expanded gammadelta-T cells combined with galectin-1 antibody on the growth of human cervical cancer xenografts in SCID mice. Clin. Invest. Med. 2010, 33:E280-289.
36. Benzaid I., Monkkonen H., Stresing V., Bonnelye E., Green J., Monkkonen J., Touraine J.L., Clezardin P. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011, 71:4562-4572.
37. Gertner-Dardenne J., Castellano R., Mamessier E., Garbit S., Kochbati E., Etienne A., Charbonnier A., Collette Y., Vey N., Olive D. Human Vgamma9Vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts. J. Immunol. 2012, 188:4701-4708.
38. Lozupone F., Pende D., Burgio V.L., Castelli C., Spada M., Venditti M., Luciani F., Lugini L., Federici C., Ramoni C., Rivoltini L., Parmiani G., Belardelli F., Rivera P., Marcenaro S., Moretta L., Fais S. Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res. 2004, 64:378-385.
39. Murphy W.J., Bennett M., Anver M.R., Baseler M., Longo D.L. Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions. Eur. J. Immunol. 1992, 22:1421-1427.
40. Shpitz B., Chambers C.A., Singhal A.B., Hozumi N., Fernandes B.J., Roifman C.M., Weiner L.M., Roder J.C., Gallinger S. High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. J. Immunol. Methods 1994, 169:1-15.
41. Sandhu J.S., Gorczynski R., Shpitz B., Gallinger S., Nguyen H.P., Hozumi N. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantation 1995, 60:179-184.
42. Thiessard F., Morlat P., Marimoutou C., Labouyrie E., Ragnaud J.M., Pellegrin J.L., Dupon M., Dabis F. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Cancer 2000, 88:1696-1702.
43. Tam H.K., Zhang Z.F., Jacobson L.P., Margolick J.B., Chmiel J.S., Rinaldo C., Detels R. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int. J. Cancer 2002, 98:916-922.
44. Oksenhendler E., Clauvel J.P., Jouveshomme S., Davi F., Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am. J. Hematol. 1998, 57:266.
45. Hocqueloux L., Agbalika F., Oksenhendler E., Molina J.M. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001, 15:280-282.
46. Thedrez A., Sabourin C., Gertner J., Devilder M.C., Allain-Maillet S., Fournie J.J., Scotet E., Bonneville M. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?. Immunol. Rev. 2007, 215:123-135.
47. Poccia F., Gioia C., Martini F., Sacchi A., Piacentini P., Tempestilli M., Agrati C., Amendola A., Abdeddaim A., Vlassi C., Malkovsky M., D'Offizi G. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. Aids 2009, 23:555-565.